Two research projects supported by the National Alopecia Areata Foundation (NAAF) were presented at the 2026 European Academy of Dermatology…
New research presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna (Sept. 28 – Oct….
Q32 Bio has announced positive 36-week topline results from Part B of its Phase 2 SIGNAL-AA clinical trial evaluating bempikibart,…
NAAF is proud to announce the recipients of our 2025 Early Career and Research Grant Awards. These investigators are dedicated…
Congratulations to NAAF award recipient Aubrey Martin on her recent publication, “Switching between Janus kinase inhibitors for treatment of alopecia…
A report recently published in the October 2025 issue of JAMA Dermatology suggests that people with alopecia areata may still benefit from trying a different Janus…
Nektar Therapeutics announced today new results from its Phase 2b REZOLVE-AA study testing rezpegaldesleukin (REZPEG)—an experimental immune-modulating drug—in adults with…
Eli Lilly (Lilly) recently shared 52-week results from its Phase 3 clinical trial examining oral baricitinib (Olumiant®) 4 mg for…
The National Alopecia Areata Foundation (NAAF) is thrilled to report that two recent Student Internship Awardees have had their NAAF-supported…
Sun Pharmaceutical Industries Limited (Sun Pharma) today announced LEQSELVI™ (deuruxolitinib) is now commercially available for the treatment of severe alopecia…
